60
Views
31
CrossRef citations to date
0
Altmetric
Original Article

Biologic and Therapeutic Determinants of Bone Mineral Density in Multiple Myeloma

, , , , , & show all
Pages 121-127 | Received 20 Mar 1998, Published online: 01 Jul 2009

References

  • Weinstein R. Bone involvement in multiple myeloma. Am J Med 1992; 93: 591–592
  • Rodriguez L H, Finkelstein J B, Schullenberger C C, Alexanian R. Bone healing in multiple myeloma with melphalan chemotherapy. Ann Int Med 1982; 76: 551–556
  • Johnston C C, Slemenda C W, Melton L J. Clinical use of bone densitometry. N Engl J Med 1991; 324: 1105–1110
  • Mariette X, Khalifa P, Ravaud P, Frija J, Laval-Jeantet M, Chastang C, et al. Bone densitometry in patients with multiple myeloma. Am J Med 1992; 93: 595–598
  • Mariette X, Bergot C, Ravaud P, Roux C, Laval-Jeantet M, Broquet J C, et al. Evolution of bone densitometry in patients with multiple myeloma treated with conventional or intensive therapy. Cancer 1995; 76: 1559–1563
  • Holmes J A, Evans W D, Coles R J, Ramashoye B, Whittaker J A. Dual energy X ray absorptiometry measurements of bone mineral density in myeloma. European J Hematology 1994; 53: 309–311
  • Roux C, Ravaud P, Cohen-Solal M, De Vernejoul M C, Guillemant S, Cherrau B, et al. Biologic, histologic and densitometric effects of oral risedronate on bone in patients with multiple myeloma. Bone 1994; 15: 41–43
  • Berenson J, Lichtenstein A, Porter L, Dimopoulos M, Bordoni R, George S, et al. Efficacy of patnidronate in reducing skeletal events in patients with advanced multiple myeloma. N Engl J Med 1996; 334: 488–495
  • Lahtinen R, Laakso M, Palva I, Virkkunen P, Elomaa I, for the Finnish Leukemia group. Randomised placebo controlled trial of clodronate in multiple myeloma. Lancet 1992; 340: 1049–1052
  • Belch A R, Bergsagel D E, Wilson K, O'Reilly S, Wilson J, Sutton D, et al. Effect of daily etidronate on osteolysis of multiple myeloma. J Clin One 1991; 9: 1397–1402
  • Jagannath S, Vesole D H, Glenn L, Crowley J, Barlogie B. Low risk intensive therapy for multiple myeloma with combined autologous bone marrow and blood stem cell transplantation. Blood 1992; 80: 1666–1672
  • Ellis R E. The distribution of active bone marrow in the adult. Phys Med Biol 1961; 5: 255–260
  • Thornton T, Ballester O, Greenfield G. Progression of bone disease in multiple myeloma patients treated with high dose therapy and autologous stem cell transplantation. Blood 1996; 88: 481a
  • Rosen L, Lichtenstein A, Heffernan M, Seaman J, Knight R, Berenson J. Serial β 2 microglobulin levels correlate with morbidity and mortality in multiple myeloma. Blood 1995; 86: 188a

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.